Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02292706 · ClinicalTrials.gov registry record
A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
A clinical trial, sponsored by Gilead Sciences.
- Terminated
- Registry status
- 1,609
- Enrollment target
NCT02292706 is a clinical trial that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 1,609 participants.
The verdict
NCT02292706 was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- 1,609 participants
- Enrollment target
Study Summary
The primary objective of this registry study is to assess the durability of sustained virologic response (SVR) and clinical progression or regression of liver disease including the incidence of hepatocellular carcinoma following SVR in participants with cirrhosis after treatment with a sofosbuvir-based regimen for HCV infection.
Interventions
- DRUG Ribavirin
- DRUG Sofosbuvir
- DRUG LDV/SOF
- DRUG SOF/VEL/VOX
- DRUG SOF/VEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,609 participants |
| Start Date | 2014-12-29 |
| Est. Completion | 2021-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02292706
The ClinicalTrials.gov registry entry for NCT02292706 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ribavirin is the first listed.
NCT02292706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02292706 about?
NCT02292706 is a clinical study titled "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection". The primary objective of this registry study is to assess the durability of sustained virologic response (SVR) and clinical progression or regression of liver disease including the incidence of hepatocellular carcinoma following SVR in participants with cirrhosis after treatment with a sofosbuvir-ba...
What is the current status of trial NCT02292706?
This trial is currently terminated. The enrollment target is 1,609 participants. The study started on 2014-12-29. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02292706?
The interventions under investigation include: Ribavirin (DRUG), Sofosbuvir (DRUG), LDV/SOF (DRUG), SOF/VEL/VOX (DRUG), SOF/VEL (DRUG).
Who is sponsoring clinical trial NCT02292706?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.